论文部分内容阅读
目的探讨原发性肝癌瘤体植入缓释顺铂同步联合三维适形放疗的临床疗效。方法选择治疗前已经确诊的原发性肝癌80例,随机分为治疗组(药物植入+放疗)和对照组(单纯放疗),主要根据瘤体大小、年龄、患者一般情况决定植入药量,放疗采用三维适形精确放疗,治疗结束后4个月评价疗效,统计两组有效率(RR)及不良反应发生率,随访观察两组生存时间(OS)并作出统计学分析。结果有效率治疗组和对照组分别为77.5%和55.0%(χ2=4.528,P=0.03),有显著性差异;生存时间治疗组为(13.95±0.618)个月,对照组为(10.775±0.631)个月(χ2=10.535,P=0.001),差异有统计学意义(P<0.05);两组之间在不良反应上无明显差异(P>0.05)。结论原发性肝癌瘤体植入缓释顺铂同步联合三维适形放疗能提高临床疗效,延长总生存,不良反应能耐受。
Objective To investigate the clinical effect of simultaneous implantation of sustained-release cisplatin and three-dimensional conformal radiotherapy on primary hepatocellular carcinoma. Methods 80 cases of primary hepatocellular carcinoma confirmed before treatment were randomly divided into treatment group (drug implantation + radiotherapy) and control group (radiotherapy alone), and the dosage was decided mainly according to tumor size, age and general condition of the patient Radiotherapy was performed with three-dimensional conformal radiotherapy. The therapeutic effect was evaluated 4 months after the end of treatment. The effective rate (RR) and incidence of adverse reactions were calculated. The survival time (OS) and the statistic analysis were followed up. Results The effective treatment group and the control group were 77.5% and 55.0% respectively (χ2 = 4.528, P = 0.03), with significant difference; the survival time was (13.95 ± 0.618) months in the treatment group and (10.775 ± 0.631) in the control group ) For months (χ2 = 10.535, P = 0.001), the difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). CONCLUSIONS: The combination of sustained-release cisplatin and three-dimensional conformal radiotherapy for primary hepatocellular carcinoma can improve the clinical curative effect, prolong the overall survival and tolerate adverse reactions.